News / Taiwan / economic_daily
Everfront Biotech Reports Record September Revenue, Surpassing Annual Targets
Health Technology · Biotechnology · economic_daily · 2026-10-08
1799, 4130
Everfront Biotech achieved record-breaking monthly revenue of NT$138 million in September, with cumulative nine-month results already exceeding the previous year's total.
What Happened
Record-Breaking Performance: Everfront Biotech announced September consolidated revenue of NT$138 million, an 80.6% year-over-year increase. This marks the second consecutive month of record-high revenue, signaling robust operational growth for the company.
Cumulative Growth: The company's cumulative revenue for the first three quarters reached NT$777 million, already surpassing the total revenue for the entire 2025 fiscal year. This significant milestone underscores the effectiveness of the company's current business strategy.
Synergy Realization: Management attributes the strong growth to the successful integration following the acquisition of GeneOnline. This merger has allowed the company to scale operations and broaden its product portfolio, creating a more comprehensive market presence.
Future Strategy: Moving forward, Everfront Biotech plans to continue leveraging its integrated resources to drive long-term growth. The company remains focused on enhancing its competitive edge and maintaining its upward trajectory in the biotechnology sector.